THE IMPACT OF TARGETED LDL CHOLESTEROL CONTROL ON ANGINA SYMPTOMS AND LONG-TERM PROGNOSIS IN PATIENTS WITH ISCHEMIC HEART DISEASE: A LITERATURE REVIEW

Authors

  • Qobilov Dostonbek Rustamovich Master's student at Tashkent State Medical University,Associate Professor, Candidate of Medical Sciences, Department of Hospital Therapy, Nephrology and Hemodialysis, Faculty No. 2 of Tashkent State Medical University,Professor of Faculty No. 2 and the Department of Hospital Therapy, Nephrology, and Hemodialysis at Tashkent State Medical University Author
  • Maksudova Malika Khamdamjanovna Master's student at Tashkent State Medical University,Associate Professor, Candidate of Medical Sciences, Department of Hospital Therapy, Nephrology and Hemodialysis, Faculty No. 2 of Tashkent State Medical University,Professor of Faculty No. 2 and the Department of Hospital Therapy, Nephrology, and Hemodialysis at Tashkent State Medical University Author
  • Jabborov Ozimboy Otakhonovich Master's student at Tashkent State Medical University,Associate Professor, Candidate of Medical Sciences, Department of Hospital Therapy, Nephrology and Hemodialysis, Faculty No. 2 of Tashkent State Medical University,Professor of Faculty No. 2 and the Department of Hospital Therapy, Nephrology, and Hemodialysis at Tashkent State Medical University Author

Keywords:

Keywords: ischemic heart disease, coronary artery disease, LDL cholesterol, low-density lipoprotein, angina pectoris, lipid-lowering therapy, statins, cardiovascular prognosis, secondary prevention, atherosclerosis.

Abstract

Ischemic heart disease (IHD) remains one of the major manifestations of atherosclerotic cardiovascular disease and is associated with recurrent angina, myocardial infarction, coronary revascularization, heart failure, and cardiovascular mortality. Low-density lipoprotein cholesterol (LDL-C) plays a central causal role in the development and progression of atherosclerotic cardiovascular disease. Therefore, targeted reduction of LDL-C represents a fundamental component of secondary prevention in patients with IHD. The aim of this literature review was to evaluate the relationship between achieving LDL-C treatment targets, angina symptoms, and long-term cardiovascular prognosis in patients with IHD. Published randomized clinical trials, meta-analyses, and international clinical guidelines concerning LDL-C lowering were reviewed. Evidence indicates that more intensive LDL-C reduction is associated with a significant decrease in major cardiovascular events. Meta-analytic data demonstrate that each 1 mmol/L reduction in LDL-C is associated with approximately a 20–22% reduction in major vascular events [1, 2]. Clinical trials such as TNT and PROVE-IT TIMI 22 further demonstrated the benefits of intensive statin therapy [3, 4]. Additional LDL-C reduction with ezetimibe or PCSK9 inhibitors may provide further cardiovascular benefit in patients who remain above target despite maximally tolerated statin therapy [5, 6]. Although LDL-C lowering primarily improves long-term prognosis rather than providing an immediate anti-anginal effect, sustained lipid control may contribute to stabilization and regression of atherosclerotic plaques and consequently reduce recurrent ischemic events.

References

1.Cholesterol Treatment Trialists’ Collaboration; Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials // The Lancet. — 2010. — Vol. 376, No. 9753. — P. 1670–1681. — DOI: 10.1016/S0140-6736(10)61350-5.

2.Cholesterol Treatment Trialists’ Collaboration; Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins // The Lancet. — 2005. — Vol. 366, No. 9493. — P. 1267–1278.

3.LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease // New England Journal of Medicine. — 2005. — Vol. 352, No. 14. — P. 1425–1435. — DOI: 10.1056/NEJMoa050461.

4.Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes // New England Journal of Medicine. — 2004. — Vol. 350, No. 15. — P. 1495–1504. — DOI: 10.1056/NEJMoa040583.

5.Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes // New England Journal of Medicine. — 2015. — Vol. 372, No. 25. — P. 2387–2397. — DOI: 10.1056/NEJMoa1410489.

6.Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease // New England Journal of Medicine. — 2017. — Vol. 376, No. 18. — P. 1713–1722. — DOI: 10.1056/NEJMoa1615664.

7.Vrints C., Andreotti F., Koskinas K.C., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes // European Heart Journal. — 2024. — Vol. 45. — P. 3415–3537.

8.Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel // European Heart Journal. — 2017. — Vol. 38, No. 32. — P. 2459–2472. — DOI: 10.1093/eurheartj/ehx144.

9.Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk // European Heart Journal. — 2020. — Vol. 41, No. 1. — P. 111–188.

10.Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome // New England Journal of Medicine. — 2018. — Vol. 379, No. 22. — P. 2097–2107. — DOI: 10.1056/NEJMoa1801174.

Downloads

Published

2026-09-23